YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
This study has been terminated.
Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00050297
First received: December 3, 2002
Last updated: June 6, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostate Cancer |
Drug: YM598 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Astellas Pharma Inc:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00050297
Locations
| Belgium | |
| University Clinic AZ | |
| Brussels, Belgium | |
| University Clinic UCL St. Luc | |
| Brussels, Belgium | |
| Czech Republic | |
| Private Urology Out-patient Ward | |
| Jablonec nad Nisou, Czech Republic | |
| Clinic of Urology, University Hospital | |
| Králové, Czech Republic | |
| Clinic of Urology, University Hospital | |
| Olomouc, Czech Republic | |
| Clinic of Urology, University Hospital | |
| Prague, Czech Republic | |
| France | |
| Hôpital Bichat, service de Urology | |
| Paris, France | |
| Germany | |
| Haingasse 22 | |
| Bad Homburg, Germany, 61348 | |
| Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus | |
| Dresden, Germany | |
| Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße | |
| Marburg, Germany | |
| Krummbogen 15 | |
| Marburg, Germany | |
| Poland | |
| Regional Hospital, Department of Urology | |
| Bydgoszcz, Poland | |
| MedSource Poland | |
| Gdansk, Poland | |
| Oncology Center, Department of Urinary Tract Cancer | |
| Warszawa, Poland | |
| Bielanski Hospital, Department of Urology | |
| Warszawa, Poland | |
| Medical University, Clinic of Urology | |
| Wroclaw, Poland | |
| Spain | |
| Complejo Hospitaliaro Juan Canalejo, Servicio de Urología | |
| Corunna, Spain | |
| Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra. | |
| Madrid, Spain | |
| Fundacion Hospital Alcorcón, Servicio Urología | |
| Madrid, Spain | |
| United Kingdom | |
| Department of Urology, Bristol Royal Infirmary | |
| Bristol, United Kingdom | |
| Department of Urology, Gartnavel Hospital | |
| Glasgow, United Kingdom | |
| Department of Urology, Norfolk & Norwich Hospital | |
| Norwich, United Kingdom | |
| Department of Urology, Taunton & Somerset Hospital | |
| Taunton, United Kingdom | |
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00050297 History of Changes |
| Other Study ID Numbers: | 598-CL-004 |
| Study First Received: | December 3, 2002 |
| Last Updated: | June 6, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013